



## Inventors

### Sidney Hecht

Director, Center for  
BioEnergetics  
The Biodesign Institute  
Arizona State University

### Ryan Schmalz

Research Technologist  
The Biodesign Institute  
Arizona State University

### Krystal Tsosie

Graduate Student  
The Biodesign Institute  
Arizona State University

## Intellectual Property

### Status:

*Patent Pending*

## Contact

*Yash Vaishnav, PhD, MBA*

Vice President

Business Development, Life  
Sciences

Arizona Technology  
Enterprises, LLC (AzTE)

P: 480.884.1648

F: 847.971.2871

[YASH@AZTE.COM](mailto:YASH@AZTE.COM)

[HEALTHSCIENCES@AZTE.COM](mailto:HEALTHSCIENCES@AZTE.COM)

## Carbohydrate-Mediated Tumor Targeting

AzTE Case # M9-146

## Invention Description

The bleomycins (BLMs) are well-known antineoplastic agents. They are particularly useful in the treatment of squamous cell carcinomas and malignant lymphomas.

The therapeutic effect of bleomycin analogues is believed to result from their selective oxidative cleavage of DNA and possibly RNA. Much of the site-specific cleavage is thought to be effected by the N-terminal metal-binding domain, the C-terminal bithiazole region, and the linker domain. The least understood structural domain of BLM is the disaccharide moiety.

Researchers at the Biodesign Institute of Arizona State University have discovered that the carbohydrate moiety of BLM, by itself, is sufficient for tumor cell targeting. Numerous highly specific analogues of this region have been produced and tested for tumor imaging and the development of novel, targeted chemotherapeutics.

## Potential Applications

- Reagents for tumor imaging
- Novel cancer chemotherapeutics

## Benefits and Advantages

- Tumor cells can be specifically imaged and targeted for chemotherapeutic destruction